<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:d5e8dc11-332c-48f6-a293-2a38d91f1efe,g:e2e4b551-c532-4284-b37c-bce0b60b831a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhvn-20250930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_40fff1a4-819c-48ad-b485-b629f3f22a32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1829cb8c-9f84-4555-b4f5-2ca14a5a9da5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_40fff1a4-819c-48ad-b485-b629f3f22a32" xlink:to="loc_us-gaap_LiabilitiesCurrent_1829cb8c-9f84-4555-b4f5-2ca14a5a9da5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_37142bc2-b3bb-4903-bc65-08238a700a36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_40fff1a4-819c-48ad-b485-b629f3f22a32" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_37142bc2-b3bb-4903-bc65-08238a700a36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e4e22740-5a8c-4e9a-8a8a-70b1c8a8eb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_40fff1a4-819c-48ad-b485-b629f3f22a32" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e4e22740-5a8c-4e9a-8a8a-70b1c8a8eb5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_f51b575a-b6a2-44e8-9e69-9c54c9340f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_40fff1a4-819c-48ad-b485-b629f3f22a32" xlink:to="loc_us-gaap_LongTermNotesPayable_f51b575a-b6a2-44e8-9e69-9c54c9340f2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2fa7e85f-df2b-4c43-93d8-e9b2a9b33065" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_ForwardContractAndDerivativeLiabilityCurrent_7e38f220-b768-4af8-9200-cbab4b75c359" xlink:href="bhvn-20250930.xsd#bhvn_ForwardContractAndDerivativeLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2fa7e85f-df2b-4c43-93d8-e9b2a9b33065" xlink:to="loc_bhvn_ForwardContractAndDerivativeLiabilityCurrent_7e38f220-b768-4af8-9200-cbab4b75c359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_752a12d0-9b4f-4658-9a0d-5fc8de3da864" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2fa7e85f-df2b-4c43-93d8-e9b2a9b33065" xlink:to="loc_us-gaap_AccountsPayableCurrent_752a12d0-9b4f-4658-9a0d-5fc8de3da864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_faeb5cc6-019e-4faa-8a46-98ac30897559" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2fa7e85f-df2b-4c43-93d8-e9b2a9b33065" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_faeb5cc6-019e-4faa-8a46-98ac30897559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_70b2913b-cb82-494e-b58d-c94a7975312f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d15aa06d-05b4-4831-a1e3-0f0c8985c8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70b2913b-cb82-494e-b58d-c94a7975312f" xlink:to="loc_us-gaap_PreferredStockValue_d15aa06d-05b4-4831-a1e3-0f0c8985c8cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_09282c5f-8b5b-4a21-8e05-21b23d1bba69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70b2913b-cb82-494e-b58d-c94a7975312f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_09282c5f-8b5b-4a21-8e05-21b23d1bba69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3ed465eb-efee-4caa-a097-370430a281c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70b2913b-cb82-494e-b58d-c94a7975312f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3ed465eb-efee-4caa-a097-370430a281c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_64f75e86-b5e6-4e37-9175-9b27e5d96e24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70b2913b-cb82-494e-b58d-c94a7975312f" xlink:to="loc_us-gaap_CommonStockValue_64f75e86-b5e6-4e37-9175-9b27e5d96e24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f63fd94d-5483-4ec5-af64-b8c0226d864d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70b2913b-cb82-494e-b58d-c94a7975312f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f63fd94d-5483-4ec5-af64-b8c0226d864d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f152cd4b-5eea-401b-8ddc-1f56f66fc700" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6e938e10-b9b2-42c2-a3c0-70ed9188ef13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f152cd4b-5eea-401b-8ddc-1f56f66fc700" xlink:to="loc_us-gaap_Liabilities_6e938e10-b9b2-42c2-a3c0-70ed9188ef13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e93c7350-7f83-4156-b248-9a1a6d496184" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f152cd4b-5eea-401b-8ddc-1f56f66fc700" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e93c7350-7f83-4156-b248-9a1a6d496184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cbb746f1-408d-47b5-9673-f552de13fa44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f152cd4b-5eea-401b-8ddc-1f56f66fc700" xlink:to="loc_us-gaap_StockholdersEquity_cbb746f1-408d-47b5-9673-f552de13fa44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_80bb2c70-6c1a-4b14-b833-bd4ac39e5f49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_758f243f-de24-455b-a62a-3ce202faa665" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_80bb2c70-6c1a-4b14-b833-bd4ac39e5f49" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_758f243f-de24-455b-a62a-3ce202faa665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_742ecd6c-a893-4aaf-825d-5beab30fa404" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_80bb2c70-6c1a-4b14-b833-bd4ac39e5f49" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_742ecd6c-a893-4aaf-825d-5beab30fa404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a333a46-d7fc-46e1-90b0-26c050410a62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_80bb2c70-6c1a-4b14-b833-bd4ac39e5f49" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a333a46-d7fc-46e1-90b0-26c050410a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_7dbd55bf-16e8-4c8f-bc08-f0129daf7d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_80bb2c70-6c1a-4b14-b833-bd4ac39e5f49" xlink:to="loc_us-gaap_OtherAssetsCurrent_7dbd55bf-16e8-4c8f-bc08-f0129daf7d7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8cbe567a-2552-4562-9561-d7facd1aa008" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_12093c06-8517-4d00-aee1-b1d7ecfaed55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8cbe567a-2552-4562-9561-d7facd1aa008" xlink:to="loc_us-gaap_AssetsCurrent_12093c06-8517-4d00-aee1-b1d7ecfaed55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3fae76b0-7457-4af8-9c96-b4d4146cdf92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8cbe567a-2552-4562-9561-d7facd1aa008" xlink:to="loc_us-gaap_Goodwill_3fae76b0-7457-4af8-9c96-b4d4146cdf92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b02b493a-af6d-4e1d-9469-808dc692ba88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8cbe567a-2552-4562-9561-d7facd1aa008" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b02b493a-af6d-4e1d-9469-808dc692ba88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_37a028be-5f5c-41cd-bb6e-03c68027b0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8cbe567a-2552-4562-9561-d7facd1aa008" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_37a028be-5f5c-41cd-bb6e-03c68027b0fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ca558679-7f54-496b-975a-a04bea78c12e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8cbe567a-2552-4562-9561-d7facd1aa008" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ca558679-7f54-496b-975a-a04bea78c12e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhvn-20250930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1b81ee56-1848-46ce-b942-fd5f8574da10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2c9e9db9-8b4c-4006-b1d9-84d025c9da10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1b81ee56-1848-46ce-b942-fd5f8574da10" xlink:to="loc_us-gaap_CostsAndExpenses_2c9e9db9-8b4c-4006-b1d9-84d025c9da10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9d8ee2f2-2c84-4f00-95ab-571775c3296c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_39d9972e-41ef-40e4-8ce5-cb664b9ca31d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9d8ee2f2-2c84-4f00-95ab-571775c3296c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_39d9972e-41ef-40e4-8ce5-cb664b9ca31d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b956693f-cc37-45ae-a9ce-ab20b2e15f07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9d8ee2f2-2c84-4f00-95ab-571775c3296c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b956693f-cc37-45ae-a9ce-ab20b2e15f07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5e36c23b-231b-4d8a-aea4-4d70c4a7e04e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_46ced758-6fb2-49b4-9271-dbd2823f78ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5e36c23b-231b-4d8a-aea4-4d70c4a7e04e" xlink:to="loc_us-gaap_NetIncomeLoss_46ced758-6fb2-49b4-9271-dbd2823f78ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6f6a43dd-3507-4ca7-9c45-df3ac5c178af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5e36c23b-231b-4d8a-aea4-4d70c4a7e04e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6f6a43dd-3507-4ca7-9c45-df3ac5c178af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83ca6f01-3102-4fe4-97fb-cf331134f115" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7ca44baa-df80-4863-8bfc-ef86a1daa05c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83ca6f01-3102-4fe4-97fb-cf331134f115" xlink:to="loc_us-gaap_OperatingIncomeLoss_7ca44baa-df80-4863-8bfc-ef86a1daa05c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_447b9277-0470-4628-b3aa-f4856b74f966" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83ca6f01-3102-4fe4-97fb-cf331134f115" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_447b9277-0470-4628-b3aa-f4856b74f966" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7b1ae011-b43c-4cdd-a220-5146702f8030" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7892b581-1ae0-402a-8d6d-305494f0babf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7b1ae011-b43c-4cdd-a220-5146702f8030" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7892b581-1ae0-402a-8d6d-305494f0babf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a54c1975-d69a-4847-b238-ecc547b7458b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7b1ae011-b43c-4cdd-a220-5146702f8030" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a54c1975-d69a-4847-b238-ecc547b7458b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhvn-20250930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36c04164-b130-4141-af28-048eee621091" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9b0dcd7a-7048-4881-adf5-41858ae4d354" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36c04164-b130-4141-af28-048eee621091" xlink:to="loc_us-gaap_ShareBasedCompensation_9b0dcd7a-7048-4881-adf5-41858ae4d354" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d50fdcfe-aee4-449d-8703-323efb492f59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36c04164-b130-4141-af28-048eee621091" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d50fdcfe-aee4-449d-8703-323efb492f59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_ProceedsFromIssuanceOfCommonStockForLicenseAgreements_5172bc6c-69f8-41dc-9500-fa9e1cd72c29" xlink:href="bhvn-20250930.xsd#bhvn_ProceedsFromIssuanceOfCommonStockForLicenseAgreements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36c04164-b130-4141-af28-048eee621091" xlink:to="loc_bhvn_ProceedsFromIssuanceOfCommonStockForLicenseAgreements_5172bc6c-69f8-41dc-9500-fa9e1cd72c29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6d63ced4-8dff-47e1-aa80-04dc62441d53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36c04164-b130-4141-af28-048eee621091" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6d63ced4-8dff-47e1-aa80-04dc62441d53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_03419717-7965-4df7-a310-6d3c174499e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36c04164-b130-4141-af28-048eee621091" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_03419717-7965-4df7-a310-6d3c174499e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_IncreaseDecreaseInFairValueOfDerivativeLiabilities_3cddb1e3-ecce-4917-b61e-4647d49ae823" xlink:href="bhvn-20250930.xsd#bhvn_IncreaseDecreaseInFairValueOfDerivativeLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36c04164-b130-4141-af28-048eee621091" xlink:to="loc_bhvn_IncreaseDecreaseInFairValueOfDerivativeLiabilities_3cddb1e3-ecce-4917-b61e-4647d49ae823" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3131523b-6e7a-42cf-8c00-dfc7ad2b310a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36c04164-b130-4141-af28-048eee621091" xlink:to="loc_us-gaap_NetIncomeLoss_3131523b-6e7a-42cf-8c00-dfc7ad2b310a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_IssuanceOfCommonSharesForAcquisitionOfResearchAndDevelopmentAsset_500eea73-f485-40e9-9f9a-7b8700524452" xlink:href="bhvn-20250930.xsd#bhvn_IssuanceOfCommonSharesForAcquisitionOfResearchAndDevelopmentAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36c04164-b130-4141-af28-048eee621091" xlink:to="loc_bhvn_IssuanceOfCommonSharesForAcquisitionOfResearchAndDevelopmentAsset_500eea73-f485-40e9-9f9a-7b8700524452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e201e064-7dc0-44b0-929b-f041f6ad4347" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36c04164-b130-4141-af28-048eee621091" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e201e064-7dc0-44b0-929b-f041f6ad4347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2469d50d-56e3-4249-9214-6c66dc10376f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36c04164-b130-4141-af28-048eee621091" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2469d50d-56e3-4249-9214-6c66dc10376f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_FairValueAdjustmentOfNotesPayable_8d3c0980-fc9d-4331-a7f6-f4cde15f4663" xlink:href="bhvn-20250930.xsd#bhvn_FairValueAdjustmentOfNotesPayable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36c04164-b130-4141-af28-048eee621091" xlink:to="loc_bhvn_FairValueAdjustmentOfNotesPayable_8d3c0980-fc9d-4331-a7f6-f4cde15f4663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_c56882f5-7250-4723-8fdb-8f2d4077a2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36c04164-b130-4141-af28-048eee621091" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_c56882f5-7250-4723-8fdb-8f2d4077a2d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_FairValueAdjustmentOfForwardContractAndDerivativeLiabilities_c24e686e-1877-4a2c-9700-c22e991fdcb6" xlink:href="bhvn-20250930.xsd#bhvn_FairValueAdjustmentOfForwardContractAndDerivativeLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36c04164-b130-4141-af28-048eee621091" xlink:to="loc_bhvn_FairValueAdjustmentOfForwardContractAndDerivativeLiabilities_c24e686e-1877-4a2c-9700-c22e991fdcb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_297c41f3-c1f1-42a4-addc-8409a53c409f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_95eb629f-9cc4-454b-b0f4-bfedf5de20d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_297c41f3-c1f1-42a4-addc-8409a53c409f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_95eb629f-9cc4-454b-b0f4-bfedf5de20d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_bcc3b3ec-4c42-40b2-8851-43c5e18260e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_297c41f3-c1f1-42a4-addc-8409a53c409f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_bcc3b3ec-4c42-40b2-8851-43c5e18260e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4f775d2c-aa8f-4fbd-924b-45ed491ff632" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_297c41f3-c1f1-42a4-addc-8409a53c409f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4f775d2c-aa8f-4fbd-924b-45ed491ff632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8b1833f0-7a73-4df7-9804-c52915cba462" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_297c41f3-c1f1-42a4-addc-8409a53c409f" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8b1833f0-7a73-4df7-9804-c52915cba462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_cc3b2b52-6d38-444a-aaff-53c2f2558e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_297c41f3-c1f1-42a4-addc-8409a53c409f" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_cc3b2b52-6d38-444a-aaff-53c2f2558e4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_77625ff9-cb3f-444f-9587-f332d9029f83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80ccfc75-733b-412d-9268-41d6c0b7ac4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_77625ff9-cb3f-444f-9587-f332d9029f83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80ccfc75-733b-412d-9268-41d6c0b7ac4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2084f76f-aee3-4f9d-8f81-d13735670533" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_77625ff9-cb3f-444f-9587-f332d9029f83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2084f76f-aee3-4f9d-8f81-d13735670533" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76108246-322b-4178-a996-d2df917b444f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_77625ff9-cb3f-444f-9587-f332d9029f83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76108246-322b-4178-a996-d2df917b444f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8517ee5a-30bd-4971-ba36-544301233555" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_77625ff9-cb3f-444f-9587-f332d9029f83" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8517ee5a-30bd-4971-ba36-544301233555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0fc2fc66-663b-4168-807b-c6bf2d8477e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_424dd884-c58a-407d-b440-9ef3a3894358" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0fc2fc66-663b-4168-807b-c6bf2d8477e5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_424dd884-c58a-407d-b440-9ef3a3894358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_d5e54e04-91ee-4f85-86d9-a5c4f7be0c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0fc2fc66-663b-4168-807b-c6bf2d8477e5" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_d5e54e04-91ee-4f85-86d9-a5c4f7be0c9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b52c1ac2-3916-466e-87dc-de309070998d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0fc2fc66-663b-4168-807b-c6bf2d8477e5" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b52c1ac2-3916-466e-87dc-de309070998d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9ef0304c-43c0-4ea5-b783-fabca1d1de55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0fc2fc66-663b-4168-807b-c6bf2d8477e5" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9ef0304c-43c0-4ea5-b783-fabca1d1de55" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="bhvn-20250930.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96ce42f3-ca00-4647-84ac-9b3614fb6c55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e33b35ca-9fd3-4c9d-9cee-560da21d3e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96ce42f3-ca00-4647-84ac-9b3614fb6c55" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e33b35ca-9fd3-4c9d-9cee-560da21d3e7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_RestrictedCashIncludedInOtherCurrentAssets_03530470-4ef9-431f-a6d8-e84942191a80" xlink:href="bhvn-20250930.xsd#bhvn_RestrictedCashIncludedInOtherCurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96ce42f3-ca00-4647-84ac-9b3614fb6c55" xlink:to="loc_bhvn_RestrictedCashIncludedInOtherCurrentAssets_03530470-4ef9-431f-a6d8-e84942191a80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_1a31ef6f-4880-43fd-9269-e6bb7b45ae27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96ce42f3-ca00-4647-84ac-9b3614fb6c55" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_1a31ef6f-4880-43fd-9269-e6bb7b45ae27" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" xlink:type="simple" xlink:href="bhvn-20250930.xsd#MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_0b804394-f526-4733-8562-0931a2abe3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2f3d032d-7b03-44b2-9764-e9f7d0fe09aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_0b804394-f526-4733-8562-0931a2abe3bc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2f3d032d-7b03-44b2-9764-e9f7d0fe09aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5f737d36-fec9-4e3c-a75e-e0196fb5222b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_0b804394-f526-4733-8562-0931a2abe3bc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5f737d36-fec9-4e3c-a75e-e0196fb5222b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b870c4c8-3403-42e6-8b70-2fa4d03d35fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_0b804394-f526-4733-8562-0931a2abe3bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b870c4c8-3403-42e6-8b70-2fa4d03d35fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" xlink:type="simple" xlink:href="bhvn-20250930.xsd#MarketableSecuritiesNetInvestmentIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_b4298fc9-65a7-46fe-afbf-b34fe90c41c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_512d3b9c-a158-41a5-890f-be36ac4da806" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeNet_b4298fc9-65a7-46fe-afbf-b34fe90c41c9" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_512d3b9c-a158-41a5-890f-be36ac4da806" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_8d912b32-9320-440d-97b3-58af45d67f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeNet_b4298fc9-65a7-46fe-afbf-b34fe90c41c9" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_8d912b32-9320-440d-97b3-58af45d67f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_2f9d9261-ab19-4d53-bd99-701ef645aafa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeDebtSecuritiesOperating_0ba5e070-66b0-4e6b-ad12-90510c0f9cba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend_2f9d9261-ab19-4d53-bd99-701ef645aafa" xlink:to="loc_us-gaap_InterestIncomeDebtSecuritiesOperating_0ba5e070-66b0-4e6b-ad12-90510c0f9cba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_d04e8bad-9778-4edf-ae3a-d44b5d1f8445" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend_2f9d9261-ab19-4d53-bd99-701ef645aafa" xlink:to="loc_us-gaap_InterestIncomeOther_d04e8bad-9778-4edf-ae3a-d44b5d1f8445" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="bhvn-20250930.xsd#FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d73767e3-cd5a-4b44-881a-a3353e6a1abe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_a364e635-f619-46ea-b933-506d3e05037e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d73767e3-cd5a-4b44-881a-a3353e6a1abe" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_a364e635-f619-46ea-b933-506d3e05037e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ddbcec5a-ed8b-415f-a083-0806b9da24d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d73767e3-cd5a-4b44-881a-a3353e6a1abe" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ddbcec5a-ed8b-415f-a083-0806b9da24d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_bc57eb60-d513-4119-9562-ae3100718f75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d73767e3-cd5a-4b44-881a-a3353e6a1abe" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_bc57eb60-d513-4119-9562-ae3100718f75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_c704f59c-3113-40ae-8b27-cdb1405f30e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_ForwardContractAndDerivativeLiabilityCurrent_f1646332-d88f-4c5b-afe8-851981a295d7" xlink:href="bhvn-20250930.xsd#bhvn_ForwardContractAndDerivativeLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_c704f59c-3113-40ae-8b27-cdb1405f30e3" xlink:to="loc_bhvn_ForwardContractAndDerivativeLiabilityCurrent_f1646332-d88f-4c5b-afe8-851981a295d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="bhvn-20250930.xsd#BalanceSheetComponentsPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e6fd1040-0142-45e6-b320-73c6556cceea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_34a64b38-afc6-4c31-a43f-88a2ffd11f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e6fd1040-0142-45e6-b320-73c6556cceea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_34a64b38-afc6-4c31-a43f-88a2ffd11f9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8ed4242c-2941-451f-82f7-5a6f648027e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e6fd1040-0142-45e6-b320-73c6556cceea" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8ed4242c-2941-451f-82f7-5a6f648027e6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails" xlink:type="simple" xlink:href="bhvn-20250930.xsd#BalanceSheetComponentsOtherNoncurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8dbb8f9a-3d4c-4813-b3bb-d2b49a0298b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2a452661-2c61-4bba-a248-2e39d6fd8ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_8dbb8f9a-3d4c-4813-b3bb-d2b49a0298b2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2a452661-2c61-4bba-a248-2e39d6fd8ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_4abe94e0-3080-46b5-93bc-cf2b156c6ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_8dbb8f9a-3d4c-4813-b3bb-d2b49a0298b2" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_4abe94e0-3080-46b5-93bc-cf2b156c6ca2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhvn-20250930.xsd#BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ddebcbe2-cd26-47d0-afc8-291f9295cee4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b00be861-bad0-4e49-bf6f-6cb56ff43c76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ddebcbe2-cd26-47d0-afc8-291f9295cee4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b00be861-bad0-4e49-bf6f-6cb56ff43c76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_AccruedClinicalTrialCostsCurrent_27aa9689-87cc-4c6e-be83-884536dc2621" xlink:href="bhvn-20250930.xsd#bhvn_AccruedClinicalTrialCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ddebcbe2-cd26-47d0-afc8-291f9295cee4" xlink:to="loc_bhvn_AccruedClinicalTrialCostsCurrent_27aa9689-87cc-4c6e-be83-884536dc2621" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b8416fb4-f25b-4575-945b-414071feb2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ddebcbe2-cd26-47d0-afc8-291f9295cee4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b8416fb4-f25b-4575-945b-414071feb2ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2920cf14-0e9b-4840-98ca-eff9dcda9500" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ddebcbe2-cd26-47d0-afc8-291f9295cee4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2920cf14-0e9b-4840-98ca-eff9dcda9500" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
